Naviscan touts PEM trial data

Jun 16, 2008

At this week's SNM meeting, PET developer Naviscan PET Systems of San Diego is highlighting clinical trial results that indicate that its PET mammography technology compares favorably to MRI in detecting breast cancer.

In a study of 136 patients using Naviscan's PEM Flex Solo II system, researchers found that PEM had a sensitivity of 91% in detecting ductal carcinoma in situ (DCIS) compared to 83% with MRI. PEM also showed better sensitivity than MRI in cancers smaller than 5 mm, and the system detected a 2-mm DCIS case that was negative on MRI, according to the company.

The research was presented by Dr. Kathy Schilling of the Center for Breast Care in Boca Raton, FL. Schilling has been studying PEM for more than two years, Naviscan said, and also is conducting a 400-patient multicenter trial comparing PEM with breast MRI that is scheduled to be completed this year.

Naviscan signs M. D. Anderson, April 3, 2008

Naviscan promotes Mirabella, February 5, 2008

Naviscan hires executives, January 8, 2008

Dilon, Naviscan settle patent dispute, December 21, 2007

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$